Abstract:The transmembrane protein Agp2, initially shown as a transporter of L-carnitine, mediates the high-affinity transport of polyamines and the anticancer drug bleomycin-A5. Cells lacking Agp2 are hyper-resistant to polyamine and bleomycin-A5. In these earlier studies, we showed that the protein synthesis inhibitor cycloheximide blocked the uptake of bleomycin-A5 into the cells suggesting that the drug uptake system may require de novo synthesis. However, our recent findings demonstrated that cycloheximide, instead, induced rapid degradation of Agp2, and in the absence of Agp2 cells are resistant to cycloheximide. These observations raised the possibility that the degradation of Agp2 may allow the cell to alter its drug resistance network to combat the toxic effects of cycloheximide. In this study, we show that membrane extracts from agp2Δ mutants accentuated several proteins that were differentially expressed in comparison to the parent. Mass spectrometry analysis of the membrane extracts uncovered the pleiotropic drug efflux pump, Pdr5, involved in the efflux of cycloheximide, as a key protein upregulated in the agp2Δ mutant. Moreover, a global gene expression analysis revealed that 322 genes were differentially affected in the agp2Δ mutant versus the parent, including the prominent PDR5 gene and genes required for mitochondrial function. We further show that Agp2 is associated with the upstream region of the PDR5 gene, leading to the hypothesis that cycloheximide resistance displayed by the agp2Δ mutant is due to the derepression of the PDR5 gene.

Mutations of Charged Amino Acids at the Cytoplasmic End of Transmembrane Helix 2 Affect Transport Activity of the Budding Yeast Multidrug Resistance Protein Pdr5p.

Mutations adjacent to the end of transmembrane helices 6 and 7 independently affect drug efflux capacity of yeast ABC transporter Pdr5p.

A Mutation In Intracellular Loop 4 Affects The Drug-Efflux Activity Of The Yeast Multidrug Resistance Abc Transporter Pdr5p

An A666G mutation in transmembrane helix 5 of the yeast multidrug transporter Pdr5 increases drug efflux by enhancing cooperativity between transport sites

Structure and efflux mechanism of the yeast pleiotropic drug resistance transporter Pdr5

A new twist in ABC transporter mediated multidrug resistance – Pdr5 is a drug/proton co-transporter

Isolation and molecular characterization of the carboxy-terminal pdr3 mutants in Saccharomyces cerevisiae

Drug susceptibilities of yeast cells are affected when expressing mutant Candida albicans drug resistance protein.

Directed Mutational Strategies Reveal Drug Binding and Transport by the MDR Transporters of Candida albicans

The Effects of Transcription Regulating Genes PDR1, pdr1-3 and PDR3 in Pleiotropic Drug Resistance

Antagonistic Changes in Sensitivity to Antifungal Drugs by Mutations of an Important ABC Transporter Gene in a Fungal Pathogen

Extracellular mutation induces an allosteric effect across the membrane and hampers the activity of MRP1 (ABCC1)

The ABC transporter Pdr5p mediates the efflux of nonsteroidal ecdysone agonists in Saccharomyces cerevisiae.

Loss of the yeast transporter Agp2 upregulates the pleiotropic drug-resistant pump Pdr5 and confers resistance to the protein synthesis inhibitor cycloheximide

The yeast ATP binding cassette (ABC) protein genes PDR10 and PDR15 are novel targets for the Pdr1 and Pdr3 transcriptional regulators

An in vitro set-up to study Pdr5-mediated substrate translocation

The multidrug resistance gene PDR1 from Saccharomyces cerevisiae.

Robust, pleiotropic drug resistance 5 (Pdr5)-mediated multidrug resistance is vigorously maintained in Saccharomyces cerevisiae cells during glucose and nitrogen limitation

ABC transporter Pdr5 is required for cantharidin resistance in Saccharomyces cerevisiae

The ABC transporter Pdr5p mediates the efflux of nonsteroidal ecdysone agonists in<i>Saccharomyces cerevisiae</i>

Positive autoregulation of the yeast transcription factor Pdr3p, which is involved in control of drug resistance